Sign inJoin waitlistJoin the waitlist

Senthil Damodaran

Associate Professor, Breast Medical Oncology · University of Texas M D Anderson Cancer Center

Credentials: · · · · · ·

History

University of Texas M D Anderson Cancer Center
Present

Ohio State University College of Medicine
2011–2013
Internal Medicine
University at Buffalo School of Medicine
2008–2011
Doctor of Medicine
1997–2001

Research

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
Journal of Clinical Oncology · 2022 · 310 citations
Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome Sequencing
Human Mutation · 2015 · 200 citations
Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
Journal of Clinical Oncology · 2020 · 173 citations

Funda Meric-Bernstam
16 papers
Bora Lim
15 papers
Jennifer Litton
15 papers
SM
Stacy Moulder
15 papers
Gaiane Rauch
13 papers
Naoto Ueno
13 papers
Vicente Valero
13 papers
Banu Arun
12 papers
Beatriz Adrada
12 papers
Clinton Yam
12 papers
Lei Huo
12 papers
Rosalind Candelaria
12 papers

Grants

University of Texas PDX Development and Trial Center
National Cancer Institute · U54
PI · $200K · University of Tx Md Anderson Can Ctr
2022–2023

Clinical trials

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
Principal investigator · Terminated · Phase 1, Phase 2
National Cancer Institute (NCI)
2021–2022
Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations
Principal investigator · Terminated · Phase 2
M.D. Anderson Cancer Center
2020–2025
Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study
Principal investigator · Terminated · Phase 2
M.D. Anderson Cancer Center
2019–2023
M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
Principal investigator · Terminated · Phase 1
M.D. Anderson Cancer Center
2018–2022